The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis

Basit Öğe Kaydı
dc.contributor.authorGulmez, Ahmet
dc.date.accessioned2024-08-04T20:53:42Z
dc.date.available2024-08-04T20:53:42Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractCranial metastasis (CM) is a serious problem in breast cancer patients. In patients with CM, quality of life is adversely affected and the survival of patients is reduced. It is also very difficult to manage breast cancer patients with cranial metastases whose life expectancy is generally 1 year or less. There is no case report in the literature of CM with more than 5 years of progression-free survival (PFS) with oncological treatment. I presented a rare case about the widespread CM developed with tamoxifen treatment in an advanced breast cancer patient who completed chemotherapy and radiotherapy after primary surgery. Systemic treatment was started as a combination of capecitabine and lapatinib after whole-brain radiotherapy was applied to the patient with extensive CM. At the end of about 3 years, there is complete response of cranial metastases, and PFS is over 5 years. The treatment was well tolerated, and she is still being followed up in the 74th month of this treatment without recurrence. There are no case reports of HER-2-positive breast cancer patients with such widespread cranial metastases in complete remission at 34 months of systemic therapy and 74 months of PFS. Our article is unique in this respect. It should be kept in mind that it is not appropriate to change the treatment plan of patients with only one case report. Although the options have increased with the use of new generation antihuman epidermal growth factor receptor 2 treatments, lapatinib can be a very effective treatment tool in selected patients.en_US
dc.identifier.doi10.4103/jcrt.jcrt_1440_21
dc.identifier.endpageS450en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issueSUPPL 1en_US
dc.identifier.pmid37147962en_US
dc.identifier.scopus2-s2.0-85159062721en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageS447en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1440_21
dc.identifier.urihttps://hdl.handle.net/11616/101346
dc.identifier.volume19en_US
dc.identifier.wosWOS:001267508000030en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBrain metastasisen_US
dc.subjectbreast canceren_US
dc.subjectHer-2-positiveen_US
dc.subjecttyrosine kinase inhibitoren_US
dc.titleThe unexpected effect of the combination of lapatinib and capecitabin in cranial metastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu